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ABSTrACT                        The blood-brain barrier, as a physical, active transport and metabolic barrier 
represents the main obstacle in the treatment of central nervous system diseases. The field 
of nanoparticle delivery systems is rapidly developing and nanocarriers seem to be promising 
for drug delivery or targeting to the brain. For testing the toxicity, uptake and transcellular 
transport of nanoparticles culture models of the blood-brain barrier are widely used, including 
immortalized brain endothelial cell lines, primary brain endothelial cells in static or dynamic 
culture conditions, and in co-culture systems with glial cells and/or pericytes. This mini-review 
gives a brief summary of blood-brain barrier co-culture models that were used for testing nano-
carriers, the types of different nanoparticle systems that were examined on blood-brain barrier 
models, and the advantages, limitations and suitability of the blood-brain barrier models for 
nanoparticle penetration studies. Acta Biol Szeged 59(Suppl.3): (2015)
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1
introduction
The blood-brain barrier, a dynamic interface separating the 
brain from systemic circulation, is the major entry route for 
therapeutic compounds to the central nervous system. Most 
drug candidates developed for neurological diseases have 
limited access to their brain targets because of the blood-
brain barrier. This barrier is composed of brain microvascular 
endothelial cells, surrounded by pericytes, astrocytic endfeet, 
perivascular microglia and neurons (Zlokovic 2008). The 
cross-talk between these cells constitutes a functional unit 
which is crucial for the formation and maintenance of the 
blood-brain barrier. The main roles of the blood-brain bar-
rier are creation of ionic homeostasis for neuronal functions, 
the supply of the brain with nutrients, protection from toxic 
insults and communication between the periphery and the 
central nervous system (Abbott et al. 2010). 
The blood-brain barrier is the most important defense 
system against xenobiotics, pathogenic microorganisms and 
other insults from the systemic circulation. However, the same 
mechanisms that protect the central nervous system also limit 
drug delivery to the brain. These mechanisms include (i) the 
restricted paracellular pathway regulated by complex interen-
dothelial tight junctions, (ii) low level of pinocytosis resulting 
in minimal non-specific transendothelial transport and (iii) 
active efflux transporters (Abbott 2010). The growing group 
of drug efflux transporters at the blood-brain barrier includes 
P-glycoprotein, brain multidrug or brain cancer resistance 
protein, several members of the multidrug resistance proteins 
and organic anion transporting polypeptides (Redzic 2011). 
The low level of paracellular flux and transendothelial vesicu-
lar trafficking result in a transport barrier for drugs which are 
hydrophilic or have a molecular mass >400 dalton (Pardridge 
2012). On the other hand brain penetration of lipophilic drugs 
is limited by the presence of efflux transporters at the luminal 
membrane of brain endothelial cells. Due to these reasons 
the blood-brain barrier prevents the brain entry of potential 
new neuropharmaceuticals including biopharmacons, nucleic 
acids and peptide or protein drugs. Improving drug delivery 
to the brain is considered essential for the future therapy of 
neurological disorders therefore novel drug delivery methods 
or systems are needed which take into account the structure 
and complex roles of the blood-brain barrier.
Strategies for central nervous system delivery 
of drugs
Several strategies have been developed to overcome or exploit 
the transport systems of the blood-brain barrier (Deli 2011). 
These strategies can be classified into three major groups sum-
marized in Figure 1. The methods that increase drug delivery 
to the brain by circumventing the blood-brain barrier include 
direct, invasive injection to brain tissue or fluids and the use of 
alternative delivery pathways, like the nasal route. Intrathecal 
or intraventricular drug administrations are effectively used 
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in the clinical treatment of pain, spasticity or central nervous 
system infections (Cook et al. 2009), however, the slow and 
ineffective diffusion in brain tissue limits the efficacy of 
this approach especially for macromolecules (Wolak et al. 
2013). A recent review summarizes novel delivery methods 
bypassing the blood-brain barrier or the blood-tumor barrier, 
among them surgically implanted polymeric matrix loaded 
with therapeutic agents and stem cell-mediated delivery of 
chemotherapeutics (Hendricks et al. 2015). At present, these 
techniques have marginal therapeutic benefit and several 
limitations such as potential perioperative complications and 
in the case of mesenchymal stem cells controversial data on 
efficacy and safety (Hendricks et al. 2015).
Intranasal delivery of small molecules or biologics to 
the central nervous system are widely investigated, and 
experimental data indicate that this alternative pathway of 
administration can be successfully exploited (Horvát et al. 
2009; Sipos et al. 2010). Preclinical and clinical studies show 
that intranasal delivery of proteins, genes or stem cells is a 
potentially useful strategy to treat neurological diseases de-
spite of the low amount of molecules that can reach the brain 
and the limited distribution to distal brain areas (Lochhead 
and Thorne 2012). 
Another approach to enhance brain delivery of molecules 
is the exploitation of the transport pathways at the blood-brain 
barrier (Fig. 1). This can be achieved either by changing the 
physico-chemical properties of molecules or nanocarriers to 
increase their delivery across the blood-brain barrier or by 
specific targeting of the physiological transport pathways of 
the blood-brain barrier. Chemical modifications enhance brain 
delivery of molecules by increasing the lipid solubility or 
cationic charge of molecules. Lipophilic small molecules or 
liposomes enter the central nervous system by lipid-mediated 
free diffusion. High lipid solubility not only increases drug 
penetration across the blood-brain barrier but also uptake 
by peripheral tissues and sequestration in the capillary bed 
resulting in decreased concentration in blood and the brain 
(Banks 2009). 
The strong negative charge created by the glycocalyx at 
the luminal surface of brain endothelial cells contributes to 
the barrier phenotype. The negative surface charge of the 
blood-brain barrier decreases the entry of negatively charged 
molecules or nanoparticles and favors the penetration of 
cationic ones by adsorptive-mediated transcytosis (Hervé et 
al. 2008). 
Specific targeting can be achieved via the physiological 
transport pathways of the blood-brain barrier (Deli 2011). 
Peptides, proteins and lipoproteins reach the brain by recep-
tor-mediated transport. Receptors for biomolecules crossing 
the blood-brain barrier, like insulin, transferrin or low density 
lipoprotein are highly expressed at the blood-brain barrier 
and were extensively characterized and tested for targeting 
large biopharmacons or nanoparticles (Pardridge 2012). 
The largest family of transporters at the blood-brain barrier 
is that of solute carriers. Several clinically used drugs, like 
l-DOPA, gabapentin and baclofen cross the blood-brain bar-
rier via the large neutral amino acid transporter LAT1 (Deli 
2011). Nanoparticles can be also targeted with ligands of 
blood-brain barrier solute carriers. As an example liposomes 
containing doxorubicin or methylprednisolone and targeted 
by gluthatione are in clinical trial phase to treat brain tumors 
or multiple sclerosis (Gaillard et al. 2012). 
Since the interendothelial tight junctions and efflux pumps 
are the two major blood-brain barrier functions limiting drug 
access to brain, their modification can be used to increase 
drug penetration (Deli 2011). Opening of interendothelial 
Figure 1. Summary of the main strategies for drug delivery to the central nervous system (CNS). BBB: blood-brain barrier. TJ: tight junction.
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tight junctions by hyperosmolar mannitol in patients with 
brain tumors results in transient and reversible increase of 
blood-brain barrier permeability and improved delivery of 
chemotherapeutics to the brain (Neuwelt et al. 2008). Short 
chain alkylglycerols can also induce quick and reversible 
opening of tight junctions at the blood-brain barrier in preclin-
ical studies and may represent a safer alternative to osmotic 
blood-brain barrier disruption (Hülper et al. 2013). 
The extrusion of drugs by efflux pumps at the blood-brain 
barrier makes the treatment of brain tumors and pharmaco-
resistant epilepsy especially difficult (Neuwelt et al. 2011). 
Efflux pump inhibitors could potentially increase the central 
nervous system delivery of antiepileptics or chemothera-
peutics, but problems with systemic and central side-effects 
make this approach unrealistic for clinical treatment at present 
(Szakács et al. 2008). Novel pharmacological strategies are 
evaluated targeting the signaling cascades responsible for 
the upregulation of blood-brain barrier efflux transporters in 
epilepsy (Potschka 2012; Janigro and Walker 2014).
Co-culture models of the blood-brain barrier
Several models have been developed to examine BBB perme-
ability. The in silico models use computational approaches for 
predicting the penetrability of new drugs and are applied to 
screen big compound libraries based on the physico-chemical 
characteristics of the molecules (Veszelka et al. 2011). The 
non-cell-based in vitro permeability models like parallel ar-
tificial membrane permeability assays (PAMPA) have been 
also proposed and evaluated for predicting passive blood-
brain barrier permeability (Avdeef et al. 2015). In silico and 
PAMPA models are technically easy, quick, high throughput 
and low cost compared to cell-based or in vivo techniques. 
These models, however, cannot be used to study cellular and 
molecular interactions and mechanisms of transport like ac-
tive influx or receptor-mediated transport, binding or metabo-
lism. To our best knowledge in silico or PAMPA models were 
not published for modelling or testing nanoparticle transfer 
across the blood-brain barrier. Animal models represent the 
most complex physiological systems for testing drug delivery 
to the brain. In vivo experiments are valuable to examine brain 
and peripheral organ distribution, metabolism, excretion and 
toxicity of both drugs and nanoparticles, but these models are 
expensive, need high level of expertise and are only used for 
testing limited number of compounds (Veszelka et al. 2011). 
Cell culture-based blood-brain barrier models are middle 
throughput systems which proved to be versatile tools in both 
basic research and permeability testing of therapeutic drugs 
and nanoparticles (Veszelka et al. 2011; Avdeef et al. 2015). 
They are more complex than the in silico or PAMPA models 
but can not replace in vivo pharmacokinetic or pharmacody-
namic studies. 
The first in vitro blood-brain barrier model, freshly iso-
lated brain capillaries, was developed by Ferenc Joó and his 
co-workers (Joó and Karnushina 1973). The development of 
the isolation method of brain microvessels was soon followed 
by a new era of culture-based blood-brain barrier models. 
The restrictive paracellular barrier and efflux pumps are 
important characteristics of the blood-brain barrier and epi-
thelial cell lines possessing these characteristics, originally 
used as test systems for gastrointestinal absorption, are also 
tested as surrogate blood-brain barrier models (Hellinger et al. 
2012). The human intestinal epithelial cell line Caco-2, and 
the dog kidney epithelial cell line MDCK transfected with the 
human MDR1 gene provide a simple and inexpensive tool for 
the screening of drug candidates for passive permeability or 
efflux transport. Both Caco-2 and MDCK cells are utilized 
to investigate transcytosis of nanoparticles (Mc Carthy et al. 
2015). However, the different cytoarchitecture and expres-
sion of tight junction and transporter proteins as compared 
to brain endothelial co-culture system limit their application 
as blood-brain barrier models (Hellinger et al. 2012). This 
consideration could be especially relevant for the selection 
of models to test targeted nanoparticles for central nervous 
system delivery. 
Immortalized brain endothelial cell lines are widely 
used as simplified culture models of the blood-brain barrier 
(Veszelka et al. 2011; Avdeef et al. 2015). Among the brain 
endothelial cell lines the mouse bEnd3, the rat RBE4 and the 
human hCMEC/D3 cell lines are the best characterized and 
the most applied for blood-brain barrier studies. The hCMEC/
D3 cell line shows decreased paracellular permeability and 
increased resistance values in comparison to other endothelial 
cell lines (Weksler et al. 2013). The uptake and transport of 
different nanoparticles was investigated on hCMEC/D3 cells 
(for review see Mc Carthy et al. 2015). Brain endothelial 
cell lines are easy to handle and cost effective blood-brain 
barrier models but their weak paracellular integrity and 
downregulation of blood-brain barrier -related genes (Urich 
et al. 2012) limit their application for drug or nanoparticle 
transport studies.
In most studies primary brain endothelial cell-based mod-
els are preferred to study blood-brain barrier functions as they 
have restrictive paracellular permeability and express vari-
ous receptors, transporters and enzymes, similarly to in vivo 
conditions (Veszelka et al. 2011; Avdeef et al. 2015). Primary 
endothelial cells are successfully cultured from brain tissues 
of different species including bovine, porcine, human, mouse 
or rat (Deli et al. 2005; Veszelka et al. 2011). No significant 
differences in culture morphology or paracellular tightness 
can be observed between these models (Avdeef et al. 2015). 
Puromycin treatment not only helped to solve the problem 
of purity in primary brain endothelial cultures by killing con-
taminating cells not expressing high levels of P-glycoprotein 
(Perrière et al. 2005), but most probably contribute to the 
recent improvements of primary blood-brain barrier models 
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by favouring capillary brain endothelial cells expressing the 
highest levels of efflux pumps and tight junction proteins 
(Avdeef et al. 2015).
The blood-brain barrier characteristics of cerebral en-
dothelial cells is induced in vivo by a cross-talk between 
endothelial cells of brain microvessels and the surrounding 
cell types, especially pericytes and glial endfeet (Abbott et al. 
2010). In primary brain endothelial cell cultures, particularly 
during long cultivation periods or after sub-culturing loss of 
blood-brain barrier characteristics is observed (Deracinois 
et al. 2013). Astroglia cells were the first cell type to induce 
blood-brain barrier phenotype in brain endothelial cells, and 
purified astroglia or mixed glial cultures are routinely used in 
the next generation of blood-brain barrier models (Deli et al. 
2005), the so called co-culture systems as shown on Figure 
2. It is well accepted, that astrocytes tighten the paracellular 
barrier and induce the expression of tight junction, transporter 
and enzyme proteins in brain endothelial cells (Abbott et al. 
2006; Deracinois et al. 2013); however, the mechanism of 
glial induction is still unknown. Since not only co-culture 
systems but also astrocyte-conditioned media are effective 
secreted growth factors may participate in the process (Abbott 
et al. 2006). Later, the inductive properties of pericytes were 
also confirmed in co-culture models and recently, triple co-
culture models (Fig. 2) mimicking the anatomical structure of 
the blood-brain barrier have been described (Nakagawa et al. 
2009; for review see Avdeef et al. 2015). Brain microvascular 
pericytes play a critical role in the development and function 
of the blood-brain barrier in both physiological and patho-
logical conditions (Winkler et al. 2011). Nakagawa and his 
co-workers were the first to demonstrate that pericytes also 
tighten the paracellular barrier of cultured brain endothelial 
monolayers and to establish and characterize a triple co-
culture blood-brain barrier model with pericytes (Nakagawa 
et al. 2009). 
The majority of the static in vitro blood-brain barrier 
models use culture inserts with a porous membrane (Fig. 
2). The membrane pore size varies between 0.4 and 3 μm, 
the smaller pores are suitable for drug penetration, while the 
larger ones are used for nanoparticle transport studies. In co-
culture models brain endothelial cells are grown on the upper 
surface of the inserts while pericytes or glial cells are cultured 
in the lower compartments (Fig. 2). This setup mimics the in 
vivo anatomy of blood-brain barrier (Abbott et al. 2010). The 
tightness of the co-culture blood-brain barrier models can be 
determined by the measurement of transendothelial electri-
cal resistance using an electrode pair and a voltohmmeter 
(Benson et al. 2013). Co-culture blood-brain barrier models 
suitable for drug testing are characterized by high resistance 
values and low permeability of tracer molecules like fluores-
cein, sucrose, albumin, or dextrans (Deli et al. 2005; Veszelka 
et al. 2011; Avdeef et al. 2015). Because co-culture models 
from primary cultures retain morphological, functional and 
metabolic blood-brain barrier characteristics they are the 
best option for transport studies at present. However, the cell 
isolation technique is time consuming, needs methodological 
Figure 2. Co-culture models of the blood-brain barrier prepared from two (double), or three cell types (triple). For the static culture condition 
culture inserts, for dynamic (flow based) condition hollow fibers are used. In both systems porous membranes divide the culture compartments. 
The morphology of brain endothelial, brain pericyte and astroglia cells is shown on phase contrast images.
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expertise and co-culture models represent a low or medium 
throughput assay (Avdeef et al. 2015).
Blood flow-induced shear stress is an important physi-
ological factor regulating vascular endothelial functions. 
Dynamic blood-brain barrier models have been developed in 
several laboratories. In the dynamic hollow-fiber flow model 
the endothelial cells are cultured on the inner side of the 
capillary tubes, while glial or other cells are situated on the 
outer side of the hollow tubes (Fig. 2). Flow-induced shear 
stress improves blood-brain barrier functionality by increas-
ing the expression of tight junction, receptor, transporter and 
enzyme proteins in brain endothelial cells (Cucullo et al. 
2011). Limitation of the system is that cell growth and cell 
coverage of the tube surface cannot be visualized. The hollow 
fiber model did not become widespread for transport studies 
most probably due to its complexity and the need for technical 
expertise (Avdeef et al. 2015). Recently new versions of the 
dynamic blood-brain barrier model have been developed; the 
microfluidic blood-brain barrier models (Avdeef et al. 2015). 
In these miniaturized co-culture systems brain endothelial 
cells and glial cells are also separated by a porous membrane, 
similarly to the static cultures. In blood-brain barrier chip 
models electrodes are built in for monitoring transendothelial 
electrical resistance and transparent materials allow the ob-
servation of cell morphology. These integrated microfluidic 
devices may represent the next generation of blood-brain 
barrier co-culture systems.
Nanoparticles designed for drug delivery to the 
central nervous system
In the last 20 years the potential of nanoparticles as nanocar-
riers is increasingly investigated for drug delivery across 
the blood-brain barrier (Kreuter 2014). An ideal nanocarrier 
would offer (i) efficient drug delivery across the blood-brain 
barrier by selective targeting, (ii) protection of the therapeutic 
cargo from enzymatic degradation, (iii) long circulation time, 
(iv) self-regulated drug release, (v) avoidance of efflux trans-
port, (vi) low immunogenicity, (vii) good biocompatibility 
and bioavailability (Mc Carthy et al. 2015). While no carriers 
fulfil all these requirements, several types of nanoparticles, 
especially targeted liposomes are getting close to clinical use 
(Gaillard et al. 2014; Mc Carthy et al. 2015). At the preclini-
cal level nanospheres, nanocapsules and micelles made from 
various components, such as lipids, polymers and metals are 
tested for delivering test molecules or drug cargos across the 
blood-brain barrier. The present review aims to focus only 
on those types of nanoparticles (Fig. 3) which were tested on 
Figure 3. Schematic drawing of different types of nanoparticles.
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co-culture models of the blood-brain barrier (Table 1).
Lipid-based systems 
Liposomes are vesicles consisting of one or more phospho-
lipid bilayers (Fig. 3) made from sphingomyelin, phosphati-
dylcholine or glycerophospholipids (Craparo et al. 2011; 
Mc Carthy et al. 2015). The structure of liposomes is similar 
to the cell plasma membranes. Hydrophilic drugs can be 
encapsulated in the aqueous core, while lipophilic drugs can 
be entrapped in the phospholipid bilayer of liposomes. Ap-
plications of conventional liposomes are limited by the poor 
control of drug release, low stability during storage, and low 
plasma circulation time due to elimination by the mononu-
clear phagocyte system (Fahmy et al. 2005). Decreasing the 
particle size (<100 nm) or modification of the surface with 
polyethylene glycol (PEG) result in extended circulation time. 
While most liposomes are not targeted, existing liposomes 
were modified for drug targeting to the brain. One such ex-
ample is the glutathione-targeted PEGylated liposome. This 
nanocarrier was investigated for the brain delivery of meth-
ylprednisolone in a rat model of multiple sclerosis (Gaillard 
et al. 2012) and of doxorubicin in brain tumor-bearing mice 
(Gaillard et al. 2014). The results indicated an increased brain 
uptake for both drugs in comparison to untargeted liposomes 
and clinical studies are in progress. Angiopeptide, a ligand 
for low-density lipoprotein receptor-related protein-1 also 
successfully targeted mitoxantrone loaded liposomes to the 
brain in tumor implanted mice (Orthmann et al. 2012) proving 
the applicability of the method. 
Solid-lipid nanoparticles are usually composed of trig-
lycerides, fatty acids and waxes (Craparo et al. 2011). They 
have advantages over other polymeric nanoparticles in terms 
of lower toxicity, higher drug loading capacity and controlled 
release over long-time periods. Unlike liposomes, they can 
encapsulate only hydrophobic drugs, which limits their use 
(Fahmy et al. 2005). Polysorbate 80 coating, which promotes 
the adsorption of apolipoprotein E, a ligand of low density 
lipoprotein receptor to the nanoparticle surface, enhances the 
uptake of solid lipid nanoparticles into the brain (Goppert et 
al. 2005).
Polymeric nanoparticles 
Among various biopolymers poly(lactic-co-glycolic acid) 
(PLGA), (poly(lactic acid) (PLA), poly-ε-caprolactone (PCL), 
chitosan, gelatin and poly-butilcynaoacrylates (PBCA) are 
some of the biodegradable biopolymers used in nanocarriers 
for delivering drugs to the brain (Kreuter 2014). Polymeric 
nanoparticles are more stable than vesicular nanocarriers and 
can protect their cargo from enzymic degradation (Mc Carthy 
et al. 2015). These solid nanoparticles have been extensively 
studied to establish the relationship between and nanoparticle 
size, surface coating, charge or targeting ligands and the abil-
ity of nanoparticles to cross the blood-brain barrier (Table 
2). Results with synthetic polymeric and human albumin 
nanoparticles indicate that they can be successfully targeted 
to cross the blood-brain barrier and enter the brain (Kreuter 
2014). The degradation of PBCA nanoparticles by hydrolysis 
leads to the production of toxic metabolites, therefore PLGA, 
PLA or albumin nanoparticles are preferably used for brain 
delivery. 
Metal nanocarriers 
Metal nanoparticles are versatile and applied in several fields 
such as medical instruments and devices, water treatment, and 
food processing. The most investigated metal nanoparticles 
Table 1. Properties of nanoparticle types tested on blood-brain barrier co-culture models.
Type of NP Composition Size Advantage Limitations
Liposomes Aqueous core surrounded by 
phospholipid bilayers 
Small unilamellar <100 nm
Large unilamellar >100 nm
Multilamellar >500 nm
Encapsulation of both 
hydrophilic and hydrophobic 
drugs 
Poor control over release of 
the drug
Low stability during storage
Solid lipid NPs Hydrophobic core surrounded 
by triglycerides, fatty acids and 
waxes 
10-500 nm Low toxicity, high drug load-
ing capacity and controlled 
release
Encapsulation of only hydro-
phobic drugs
Polymeric NPs Natural or synthetic degradable 
polymers
10-1000 nm Stability against enzymatic 
metabolism 
Some have toxic hydrolysis 
by-products
Metal NPs Gold, and titanium or iron 
oxides
1-100 nm Gold and titanium NPs: inert, 
ultra small size, absorb and 
scatter near-infrared light
Iron NPs: can be paramag-
netic
Gold and titanium NPs: con-
troversy on carcinogenicity
Iron NPs: may induce oxida-
tive stress
Quantum dots Colloidal semi-conductor nanos-
cale crystals
2-50 nm Fluorescent targeting and 
imaging, long-term visu-
alization, extremely high 
stability to photobleaching
Cytotoxic in high concentra-
tions
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Table 2. Summary of experiments testing nanoparticles on co-culture BBB models.
Nanoparticle 
type
Composi-
tion
Targeting ligand 
or coating
Cargo Nanopar-
ticle size 
(nm)
Brain 
endothelial 
cells
Co-culture 
cell type
Result Ref.
Lipid NPs
Fluorescent 
magneto-
liposomes
Transferrin No 130 Primary 
human 
Human 
astroglia
Increased NP 
permeability
Ding et al. 
2014
Solid lipid 
NPs
Solid lipid Anti-insulin recep-
tor mAb
Carmustine 100-450 Primary 
human 
Human 
astroglia
Increased NP 
uptake and 
permeability
Kuo et al. 
2013b
Solid lipid Anti-insulin recep-
tor mAb
Saquinavir 120-450 Primary 
human 
Human 
astroglia
Increased NP 
uptake and 
permeability
Kuo et al. 
2013a
Metal NPs
Fe3O4 
(magnetic)
No BDNF 60 Primary 
human 
Human 
astroglia
Magnetically 
guided NP per-
meability
Pilakka et al. 
2013
Gold Peptide recog-
nizing trasferrin 
receptor
β-sheet 
breaker 
peptide
15 Primary 
bovine 
Rat astroglia Increased NP 
permeability
Prades et al. 
2012
TiO2 No No 25 Primary rat Rat astroglia NP uptake, 
transport and 
cellular toxicity
Brun et al. 
2012
Polymer NPs
PBCA Cationic charge, 
lipid coating
Albumin 60 Primary 
bovine
Rat glia Increased NP 
transcytosis
Fenart et al. 
1999
PBCA Polysorbate-80 Dalargin 200 Primary 
bovine
Rat glia Increased BBB 
model perme-
ability
Olivier et al. 
1999
PBCA Polysorbate-80 Dalargin 300 Primary 
bovine 
Rat astroglia No toxicity Kreuter et al. 
2003
PBCA Ligand of diphthe-
ria toxin receptor 
(CRM197)
Zidovudine 87, 163, 
195
Primary 
human 
Human 
astroglia
Increased NP 
uptake and 
permeability
Kuo et al. 
2012b
PHDCA PEG No 166, 171 Primary rat Rat astroglia Increased NP 
translocation
Garcia et al. 
2005
PEG-PLA Cationic BSA 6-Coumarin 100 Primary rat Rat astroglia Increased NP 
uptake
Lu et al. 2005
PLGA Tween-20, BSA, 
Transferrin 
DiI fluores-
cent dye
63-90 Primary 
bovine 
Rat astroglia Increased NP 
endocytosis
Chang et al. 
2009
MMA-SPM bradykinin type II 
receptor agonist
Stavudine, 
Delavirdine, 
Saquinavir
48, 13, 8 Primary 
human 
Human 
astroglia
Increased NP 
uptake and 
permeability
Kuo et al. 
2012a
Quantu dots
Quantum 
dots
No siRNA for 
MMP9
15-20 Primary 
human 
Human 
astroglia
NP uptake and 
MMP9 gene 
silencing
Bonoiu et al. 
2009
Quantum 
rods
Transferrin No 26 nm 
length, 
6.5 nm 
width
Primary 
human 
Human 
astroglia
Concentration- 
and time-
dependent NP 
crossing
Xu et al. 2008
Silica NPs 
and quan-
tum dots
Amino-, carboxyl-, 
and PEGylated-
Qdots
No 30, 100, 
400
Primary rat Rat astroglia 
and rat 
pericyte
Size- and amino 
group depend-
ent NP perme-
ability
Hanada et al. 
2014
BSA: bovine serum albumin. CRM197: a ligand of diphtheria toxin receptor. mAb: monoclonal antibody. MMA-SPM: methylmethacrylate–sulfopropylmethacrylate. 
MMP9: matrix metalloproteinase-9. N.D.: no data. PBCA: poly(butylcyanoacrylate. PEG: polyethylene glycol. PHDCA: poly(hexadecylcyanoacrylate. PLA: poly-lactide. 
PLGA: poly(lactic-co-glycolic acid). Qdots: quantum dots. RMP-7 (Cereport): bradykinin type II receptor agonist.
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for central nervous system delivery include gold, titanium 
and iron oxides (Mc Carthy et al. 2015). Gold nanoparticles 
are inert and can be produced in sizes as small as 1-10 nm. 
Their imaging is easy because they absorb and scatter near-
infrared light and they are electron dense in transmission 
electron microscopy. Gold nanorods can deliver siRNA for 
gene silencing to brain endothelial cells (Bonoiu et al. 2009) 
and target the transferrin receptor for crossing the blood-brain 
barrier (Prades et al. 2012). 
Iron oxide nanoparticles are investigated for various 
biomedical applications targeting the brain, including imag-
ing, tumor therapy, and drug delivery (Ito et al. 2005). The 
superparamagnetic properties enable both the tracing of 
nanoparticles by magnetic resonance imaging, and targeting 
to selected tissues or areas with application of magnetic fields 
(Ito et al. 2005). Using an iron nanocarrier and magnetic 
guidance brain derived neurotrophic factor was delivered 
across a culture model of the blood-brain barrier (Pilakka et 
al. 2013). Uncoated iron nanoparticles may aggregate which 
is enhanced by external magnetic field. Surface modification 
of iron nanoparticles like polymer coating is necessary to 
prevent aggregation and vectors or magnetic guidance are 
needed for targeting (Ito et al. 2005).
Titanium dioxide nanoparticles can be found in various 
products like paints, food additives and cosmetics. Since they 
may pose an environmental risk their toxicity was tested on 
a blood-brain barrier model. Titanium dioxide nanoparticles 
damage the integrity of brain endothelial cell layers (Brun 
et al. 2012). Although metal nanoparticles are generally 
considered safe, the carcinogenicity of gold and titanium 
nanoparticles is controversial, and iron nanoparticles may 
induce oxidative stress.
Quantum dots
Quantum dots are colloidal semi-conductor nanocrystals 
(<50 nm) with excellent fluorescent properties including high 
brightness, stability against photobleaching, broad absorption 
spectra, and a tunable and narrow emission spectrum (Mc 
Carthy et al. 2015). The surface of the quantum dots can be 
easily functionalized by PEG, amino, or carboxyl groups. 
Among these modifications the presence of amino groups 
increased the brain endothelial permeability of quantum dots 
using a triple co-culture blood-brain barrier model (Hanada 
et al. 2014). 
Practical considerations for the design of 
nanoparticles for central nervous system 
delivery and their testing on co-culture models 
of the blood-brain barrier
Uptake or transport of nanoparticles at the blood-brain bar-
rier is dependent on physicochemical characteristics, such as 
size, surface charge, coating or functionalization by targeting 
ligands (Kreuter 2014). The size of nanocarriers developed 
for brain drug delivery ranges from 10 to 1000 nm (Craparo 
et al. 2011). No linear correlation between nanoparticle size 
and permeability can be established (Kreuter 2014). Using 
fluorescent silica nanoparticles of 30, 100 and 400 nm size 
the permeability coefficient of the 30 nm nanoparticles was 
the highest on a triple blood-brain barrier co-culture model 
(Hanada et al. 2014) (Table 2). This result is in agreement 
with data of animal experiments testing the effect of nano-
particle size on distribution to brain: accumulation of small 
nanoparticles (10-50 nm) in brain tissue was observed as 
compared to nanoparticles of >200 nm in size (Hillyer et al. 
2001). 
In addition to size, the surface charge also affects the 
uptake and transcytosis of nanoparticles. The luminal surface 
of brain endothelial cells contains glycocalyx residues that 
establish a strong negative charge which contributes to the 
barrier phenotype (Hervé et al. 2008). Cationic molecules or 
drugs have higher penetration across the blood-brain barrier 
mediated by adsorptive mediated transcytosis (Deli 2011). 
Cationization is one of the methods to increase nanoparticle 
delivery across the blood-brain barrier. Lipid coated cationic 
nanoparticles enhanced the transport of albumin in a blood-
brain barrier co-culture model (Fénart et al. 1999) (Table 2). 
Increased brain penetration is observed for cationic nanopar-
ticles in animal studies, too (Lu et al. 2005), but the excess 
positive charge also leads to the formation of a protein corona 
in blood and rapid removal of the particles from the circula-
tion by the phagocyte system (Mc Carthy et al. 2015). Coating 
of cationic nanocarriers by neutral, hydrophilic polymers such 
as PEG results in enhanced stability, prolonged circulation 
time (Mc Carthy et al. 2015) and increased passage across a 
blood-brain barrier model (Garcia-Garcia et al. 2005). 
Receptor-mediated transport at the blood-brain barrier is 
responsible for the brain penetration or clearance of peptides 
and proteins, like transferrin, leptin, ghrelin or low density 
lipoprotein (Abbott et al. 2010; Campos-Bedolla et al. 2014). 
This transcytotic caveolae-mediated pathway allows the spe-
cific targeting of large molecules, such as biopharmaceuticals 
or nanoparticles to the central nervous system (Deli 2011; 
Pardridge 2012). Nanoparticles targeting the transferrin re-
ceptor at the blood-brain barrier can be labeled by transferrin 
(Xu et al. 2008; Chang et al. 2009; Ding et al. 2014), or by 
a peptide sequence recognizing the receptor (Prades et al. 
2012). All these particles show increased permeability across 
blood-brain barrier co-culture models (Table 2). Monoclonal 
antibodies which bind to insulin receptor increase the penetra-
tion of solid lipid nanoparticles across brain endothelial cells 
and the brain delivery of the drug cargo in animals (Kuo et al. 
2013a, 2013b) similarly to the effect of insulin as targeting 
ligand for nanoparticles (Shilo et al. 2014). A blood-brain 
barrier receptor for membrane-bound precursor of heparin 
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binding epidermal growth factor-like growth factor also acts 
as a receptor for diphteria toxin. A safe, clinically used ligand 
of this blood-brain barrier receptor, CRM197 is effective to 
target drug-carrying polymer nanoparticles across brain en-
dothelial cells (Kuo et al. 2012b). Coating nanoparticles by 
polysorbate 80 also results in enhanced penetration across 
the blood-brain barrier (Olivier et al. 1999; Kreuter et al. 
2003). The mechanism is the adsorption of apolipoprotein E 
from plasma to the surface of injected nanoparticles followed 
by receptor mediated transcytosis via lipoprotein receptors, 
like low density lipoprotein receptor across the blood-brain 
barrier (Goppert et al. 2005; Kreuter 2014). Active targeting 
to the brain can be also achieved by ligands of blood-brain 
barrier solute carriers, like glutathione for both liposomal 
drug formulations (Gaillard et al. 2012, 2014) and polymeric 
nanoparticles (Grover et al. 2014). 
Another approach is the use of tight junction modifying/
opening molecules (Fig. 1), such as the bradykinin agonist 
RMP7, which enhances the delivery of antiretroviral drugs 
loaded in polymeric nanoparticles when tested on blood-brain 
barrier co-cultures (Kuo et al. 2012a). These data indicate that 
all major strategies used for drug delivery to central nervous 
system can be successfully applied to nanoparticle delivery 
or targeting. Systematic studies comparing active targeting 
by different ligands or different delivery strategies across 
blood-brain barrier models would be necessary to evaluate 
the efficacy of these methods.
Co-culture models of the blood-brain barrier are con-
sidered the most complex and also the most reliable for 
prediction of drug penetration to brain based on in vivo-in 
vitro correlations (Veszelka et al. 2011; Hellinger et al. 2012; 
Avdeef et al. 2015). Such correlations are not available for 
nanocarriers, but a couple of studies provide data on nano-
particle delivery using both animal and culture blood-brain 
barrier models (Mc Carthy et al. 2015). For most cases there 
is concordance between the results, especially, when the same 
species is used for both culture and animal studies and when 
primary cultures are used for blood-brain barrier models. 
Discrepancy between results arises from the use of brain 
endothelial cell lines as culture blood-brain barrier models, 
or different species for in vivo and in vitro experiments. There 
are two likely explanations of these contradictions: (i) brain 
endothelial cell lines express low levels of key blood-brain 
barrier transporters, like glucose transporter-1 or P-glycopro-
tein as compared to freshly isolated brain caillaries or primary 
cultures (Urich et al. 2012) and (ii) different blood-brain bar-
rier transporter and receptor levels can be detected in different 
species (Uchida et al. 2011). Based on these considerations 
immortalized brain endothelial cell lines or epithelial cell 
line-based surrogate models are not recommended for testing 
nanoparticle transport. Such simplified systems may be used 
for preliminary screening but results need to be confirmed 
on more complex blood-brain barrier culture models. There 
are no data on dynamic blood-brain barrier or chip models 
to test nanoparticle passage, but these systems can be useful 
to reveal the effect of flow on nanoparticle interaction with 
brain endothelial cells. In addition to uptake and transport 
experiments cellular toxicity tests are important applications 
of blood-brain barrier models and are recommended as the 
first step of all nanoparticle studies.
Conclusion
In summary, nanoparticle based drug delivery to brain is 
a rapidly expanding research field with a great therapeutic 
potential. Blood-brain barrier co-culture models are useful 
tools to test the toxicity, uptake and transcellular transport of 
different nanocarriers developed for central nervous system 
drug targeting or delivery. In addition to providing estimation 
for brain penetration, the mechanism of the delivery or target-
ing can be also revealed by these models. Active targeting 
of vesicular or solid nanoparticles by ligands of receptors or 
transporters present at the blood-brain barrier enhances brain 
delivery in preclinical models and clinical studies on actively 
targeted nanocarriers for treatment of neurological diseases 
including brain tumors are in progress. Culture-based blood-
brain barrier models will greatly contribute to the develop-
ment of novel, even more specific nanoparticle drug delivery 
platforms to treat central nervous system diseases. 
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